Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study.
Anemia
Myeloma
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
27
09
2020
revised:
18
12
2020
accepted:
27
12
2020
pubmed:
17
1
2021
medline:
2
4
2021
entrez:
16
1
2021
Statut:
ppublish
Résumé
Multiple myeloma (MM) patients presenting with anaemia as their sole clinical manifestation are rare and not fully defined. Retrospective multi-site study comparing the characteristics and outcome of MM patients with anaemia only with matched patients, presenting with multi-organ disease. Anaemia-only patients had a higher percentage of bone marrow monoclonal plasma cells group (median 60% [IQR 42-80%] vs. 37% [IQR 17-65%], respectively; p < 0.001), and a lower responsiveness to treatment (≥VGPR rates were 54% vs 74%, p = 0.049). Median survival in anaemia only patients was 65.9 ± 6.9 vs 83.4 ± 8.8 months in matched control patients (P = n.s). MM patients presenting with anaemia only represents a unique, potentially less favorable population.
Sections du résumé
BACKGROUND
Multiple myeloma (MM) patients presenting with anaemia as their sole clinical manifestation are rare and not fully defined.
METHODS
Retrospective multi-site study comparing the characteristics and outcome of MM patients with anaemia only with matched patients, presenting with multi-organ disease.
RESULTS
Anaemia-only patients had a higher percentage of bone marrow monoclonal plasma cells group (median 60% [IQR 42-80%] vs. 37% [IQR 17-65%], respectively; p < 0.001), and a lower responsiveness to treatment (≥VGPR rates were 54% vs 74%, p = 0.049). Median survival in anaemia only patients was 65.9 ± 6.9 vs 83.4 ± 8.8 months in matched control patients (P = n.s).
CONCLUSIONS
MM patients presenting with anaemia only represents a unique, potentially less favorable population.
Identifiants
pubmed: 33453475
pii: S0145-2126(20)30203-4
doi: 10.1016/j.leukres.2020.106498
pii:
doi:
Substances chimiques
Bortezomib
69G8BD63PP
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
106498Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.